Procedural outcomes
PVI was successfully achieved in all 30 patients with paroxysmal (57%)
and persistent (37%) AF. No major procedure-related adverse events,
such as cardiac tamponade, stroke or esophageal injury, occurred.
Patients seen in follow-up up to 6 months post-ablation remained in
sinus rhythm. Anti-arrhythmic drug use at 6 months post-ablation was
continued in 53% of patients in the Agilis group and only 27% of
patients in the SureFlex group; however, this did not reach statistical
significance.